Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update
- Clinical advancements in autoimmune diseases and genetically defined forms of B-cell lymphoma -
- Details announced for planned clinical development of IMO-8400 in polymyositis and dermatomyositis –
- Plans announced to identify drug candidates from its gene silencing oligonucleotide platform -
"2013 was a year of transformation for Idera and we are very pleased to
have continued this positive momentum into 2014," reflected
Program Updates
Over the past year, Idera has significantly strengthened its pipeline, which includes clinical programs designed to inhibit the over-activation of Toll-like receptors (TLRs) across a number of disease areas, and a preclinical program developing gene silencing oligonucleotides (GSOs) designed to inhibit the production of disease-associated proteins by targeting RNA.
Autoimmune Diseases
-
Idera announced today its plans to initiate clinical development of
its lead compound, IMO-8400, for the treatment of patients with
polymyositis and dermatomyositis in the first half of 2014. This
represents further progress of a previously announced strategy to
expand the clinical development program for IMO-8400 into orphan
autoimmune diseases, as polymyositis and dermatomyositis are both
serious autoimmune conditions with significant unmet medical needs.
Both polymyositis and dermatomyositis have been designated as
orphan diseases by the
U.S. Food and Drug Administration (FDA ). -
Idera is continuing to conduct a Phase 2 trial of IMO-8400 in patients
with moderate-to-severe plaque psoriasis. This fully enrolled study is
designed to evaluate safety, tolerability and clinical activity, based
on changes in psoriasis area severity index (PASI) scores. Idera
anticipates that top-line data from the first three dosing cohorts
will be available by the end of the first quarter of 2014. Based on
blinded safety data from the trial, in
October 2013 , Idera expanded the trial to evaluate a higher dose of 0.6 mg/kg and placebo in up to 12 patients and the Company anticipates that top-line data from this cohort will be available in the second quarter of 2014. -
Idera has also expanded its pipeline of TLR antagonist candidates with
the advancement of IMO-9200, for the potential use in selected
autoimmune disease indications. The Company plans to submit an
Investigational New Drug (IND) application to the
FDA and initiate a Phase 1 trial for IMO-9200 in the second half of 2014.
Genetically Defined Forms of B-cell Lymphoma
Idera’s program in genetically defined forms of B-cell lymphoma is based on recent reports from several independent investigators offering evidence that in certain B-cell lymphomas the presence of the MYD88 L265P mutation led to over-activation of TLR7 and TLR9 signaling and that blocking these TLRs accelerated tumor cell death.
-
In
December 2013 , Idera was cleared to open enrollment in its Phase 1/2 trial of IMO-8400 in patients with Waldenström’s macroglobulinemia, a form of non-Hodgkin lymphoma. The trial is designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients who have a history of relapse or failure to respond to one or more prior therapies. The Company anticipates that patient treatment in this trial will begin in the first half of 2014. - Idera also intends to initiate clinical development of IMO-8400 in patients with diffuse large B-cell lymphoma (DLBCL) harboring the MYD88 L265P mutation. The Company has recently submitted a protocol for a Phase 1/2 trial in this indication.
Gene Silencing Oligonucleotides
Idera is also continuing its advancement of its GSO platform, designed to inhibit the production of disease-associated proteins by targeting RNA in a wide range of therapeutic areas. The Company believes that its GSO platform could offer an improved therapeutic index, based on efficient delivery without carrier, reduced immunotoxicity and increased potency.
Idera has conducted extensive preclinical studies which validate its GSO technology, and is in the process of prioritizing disease indications for clinical development. Idera expects to announce its two disease targets in the second half of 2014.
Recent Corporate Highlights
Financing
In
Management Addition
In
Board of Directors Additions
In
In
In
Financial Results
Fourth Quarter Results
Net loss applicable to common stockholders for the three months ended
Full Year Results
Net loss applicable to common stockholders for the year ended
As of
Webcast and Conference Call
Idera will host a conference call today at
In order to participate in the conference call, please dial 1-866-271-6130 (domestic) or 1-617-213-8894 (international) and provide the access code 13838305. The live webcast can be accessed under “Investor Events” in the Investors section of the Company’s website at www.iderapharma.com or you may use the link http://edge.media‐server.com/m/p/tni65ic2/lan/en.
A replay of the call will be available at
Investors section of Idera’s website at www.iderapharma.com
About
Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). Idera is developing these therapeutics for the treatment of genetically defined forms of B-cell lymphoma and for autoimmune diseases with orphan indications. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides that it has created using its proprietary technology, to inhibit the production of disease-associated proteins by targeting RNA. More information on Idera is available at www.iderapharma.com.
Forward Looking Statements
This press release includes statements concerning
Idera Pharmaceuticals, Inc. | |||||||||||||||||||||
Condensed Statements of Operations | |||||||||||||||||||||
(In thousands, except per share data) | |||||||||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||||||||
December 31, | December 31, | ||||||||||||||||||||
2013 | 2012 | 2013 | 2012 | ||||||||||||||||||
(Unaudited) | |||||||||||||||||||||
Revenues | $ | 4 | $ | 11 | $ | 47 | $ | 51 | |||||||||||||
Operating Expenses | |||||||||||||||||||||
Research & Development | 3,640 | 3,078 | 10,475 | 13,673 | |||||||||||||||||
General & Administrative | 2,436 | 1,265 | 7,741 | 6,279 | |||||||||||||||||
Total Operating Expenses | 6,076 | 4,343 | 18,216 | 19,952 | |||||||||||||||||
Loss from Operations | (6,072 | ) | (4,332 | ) | (18,169 | ) | (19,901) | ||||||||||||||
Decrease in Fair Value of Warrant Liability | - | 569 | - | 675 | |||||||||||||||||
Other, net | (18 | ) | (35 | ) | (57 | ) | (14) | ||||||||||||||
Net Loss | (6,090 | ) | (3,798 | ) | (18,226 | ) | (19,240) | ||||||||||||||
Loss on Extinguishment of Preferred Stock, Preferred Stock Accretion and Dividends |
279 | 2,730 | 2,866 | 3,210 | |||||||||||||||||
Net Loss Applicable to Common Stockholders | $ | (6,369 | ) | $ | (6,528 | ) | $ | (21,092 | ) | $ | (22,450) | ||||||||||
Basic and Diluted Net Loss Per Common Share Applicable to Common Stockholders | $ | (0.10 | ) | $ | (0.24 | ) | $ | (.48 | ) | $ | (0.81) | ||||||||||
Shares Used in Computing Basic and Diluted Net Loss Per Common Share Applicable to Common Stockholders | 63,795 | 27,642 | 43,906 | 27,639 | |||||||||||||||||
Idera Pharmaceuticals, Inc. | ||||||||||||
Condensed Balance Sheet Data | ||||||||||||
(In thousands) | ||||||||||||
At December 31, | ||||||||||||
2013 | 2012 | |||||||||||
Cash, Cash Equivalents | ||||||||||||
& Investments | $ | 35,592 | $ | 10,096 | ||||||||
Other Assets | 1,275 | 727 | ||||||||||
Total Assets | $ | 36,867 | $ | 10,823 | ||||||||
Total Liabilities | $ | 4,415 | $ | 4,196 | ||||||||
Redeemable Preferred Stock | - | 5,921 | ||||||||||
Stockholders' Equity | 32,452 | 706 | ||||||||||
Total Liabilities, Redeemable Preferred | ||||||||||||
Stock & Stockholders' Equity | $ | 36,867 | $ | 10,823 | ||||||||
Source:
Stern Investor Relations, Inc.
Sarah McCabe, 267-909-9237
sarah@sternir.com